BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37686552)

  • 1. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan.
    Tseng CH
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    Tseng CH
    BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis.
    Tseng CH
    J Clin Med; 2018 Sep; 7(10):. PubMed ID: 30262775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients.
    Tseng CH
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus.
    Tseng CH
    Sci Rep; 2021 Jun; 11(1):12400. PubMed ID: 34117321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study.
    Tseng CH
    World J Mens Health; 2023 Jan; 41(1):119-128. PubMed ID: 35274506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone.
    Tseng CH
    Aging Dis; 2020 May; 11(3):658-667. PubMed ID: 32489710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes.
    Yen FS; Wei JC; Hung YT; Hsu CY; Hwu CM; Hsu CC
    Front Microbiol; 2023; 14():1118000. PubMed ID: 36876083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin.
    Tseng CH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
    Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
    Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
    Tseng CH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():285-295. PubMed ID: 35177899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Use Is Associated With a Lower Incidence of Hospitalization for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.
    Tseng CH
    Front Med (Lausanne); 2020; 7():592901. PubMed ID: 33693008
    [No Abstract]   [Full Text] [Related]  

  • 14. Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients.
    Tseng CH
    Aging (Albany NY); 2019 May; 11(9):2724-2734. PubMed ID: 31085804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Metformin on Lower Urinary Tract Symptoms in Male Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Taiwan.
    Tseng CH
    World J Mens Health; 2023 Jul; 41(3):680-691. PubMed ID: 36593711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease.
    Yen FS; Wei JC; Yang YC; Hsu CC; Hwu CM
    Front Med (Lausanne); 2021; 8():729518. PubMed ID: 34957135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.